NeuroPace (NPCE) said late Monday that it expects "minimal impact" to its operations and financial results from the Trump administration's tariffs .
The medical device company said it manufactures and sells the "vast majority" of its devices in the US and has "limited" supply chain activities outside the country for its responsive neurostimulation System.
The firm expects "no material" impact on gross margin for DIXI Medical SEEG products.
It expects "minimal impact" to gross margin for fiscal 2025 and is reiterating its gross margin guidance for 2025.
NeuroPace will report Q1 financial results after market close on May 13.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.